Ridgeback Capital Investments adds Trillium Therapeutics (TRIL) to its portfolio

Trillium Therapeutics (TRIL) : Ridgeback Capital Investments added new position in Trillium Therapeutics during the most recent quarter end. The investment management firm now holds 370,537 shares of Trillium Therapeutics which is valued at $3,812,826 , the company said in a statement filed on Aug 12, 2016 with the SEC.Trillium Therapeutics makes up approximately 27.84% of Ridgeback Capital Investments’s portfolio.

Other Hedge Funds, Including , K2 Principal Fund added TRIL to its portfolio by purchasing 14,614 company shares during the most recent quarter which is valued at $150,378. Trillium Therapeutics makes up approx 0.04% of K2 Principal Fund’s portfolio.Oxford Asset Management reduced its stake in TRIL by selling 52,552 shares or 35.55% in the most recent quarter. The Hedge Fund company now holds 95,267 shares of TRIL which is valued at $957,433. Trillium Therapeutics makes up approx 0.04% of Oxford Asset Management’s portfolio.

Trillium Therapeutics closed down -0.05 points or -0.39% at $12.66 with 46,252 shares getting traded on Monday. Post opening the session at $13.0324, the shares hit an intraday low of $12.35 and an intraday high of $13.0324 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

Many Wall Street Analysts have commented on Trillium Therapeutics. Ladenburg Thalmann Initiated Trillium Therapeutics on Aug 3, 2016 to “Buy”, Price Target of the shares are set at $18.

Leave a Reply

Trillium Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Trillium Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.